Lomass Soliman | Young Researcher Award | Pharmaceutical Sciences

Published on by Network Science

Young Researcher Award

 Lomass Soliman
Affiliation Institute of Pharmaceutical Technology and Regulatory Affairs
Country Hungary
Scoholar ID 6osAAAAJ
Documents 5
Citations 23
h-index 3
Subject Area Pharmaceutical Sciences
Event International Research Awards on Network Science & Graph Analytics

Lomass Soliman
Institute of Pharmaceutical technology and regulatory affairs

 Lomass Soliman The recognition is associated with the International Research Awards on Network Science & Graph Analytics and is intended to highlight emerging researchers whose scholarly activities demonstrate developing expertise, research engagement, and potential for continued contribution to their discipline.

Abstract

This academic recognition profile presents Lomass Soliman in the context of the Young Researcher Award. Soliman is affiliated with the Institute of Pharmaceutical Technology and Regulatory Affairs at the University of Szeged in Hungary and works within the broad field of pharmaceutical sciences. The supplied scholarly indicators record five documents, 23 citations, and an h-index of 3. These metrics describe an emerging publication and citation record and may be considered alongside the quality, originality, relevance, and documented contribution of individual research outputs. Bibliometric indicators are generally most informative when interpreted together with qualitative evidence of scholarly contribution rather than as standalone measures of research quality. [2]

Keywords

  • Lomass Soliman
  • Young Researcher Award
  • Pharmaceutical Sciences
  • Pharmaceutical Technology
  • Regulatory Affairs
  • University of Szeged
  • Research Recognition
  • Bibliometric Indicators

Introduction

Young researcher recognition generally emphasizes the development of an independent scholarly profile, research productivity, methodological competence, and potential for sustained contribution. Within pharmaceutical sciences, research may encompass drug development, pharmaceutical formulation, delivery systems, analytical methods, manufacturing technologies, quality considerations, and regulatory frameworks. The Institute of Pharmaceutical Technology and Regulatory Affairs at the University of Szeged provides an academic setting relevant to these interdisciplinary areas.

Evaluation of early-career researchers benefits from combining quantitative measures with qualitative assessment. Publication counts and citation indicators can provide useful evidence of scholarly visibility, while peer-reviewed research, methodological rigor, originality, reproducibility, and relevance offer additional dimensions for evaluation. [1]

Research Profile

Lomass Soliman’s supplied academic information places the researcher within Pharmaceutical Sciences, with an institutional affiliation in pharmaceutical technology and regulatory affairs. The available Google Scholar identifier is BPP-6osAAAAJ, while the supplied bibliometric record reports five documents, 23 citations, and an h-index of 3. [3]

The combination of pharmaceutical technology and regulatory affairs represents an interdisciplinary research environment in which scientific development can intersect with formulation, product quality, evaluation, and regulatory considerations. Further assessment of the research profile would appropriately consider the specific topics, study designs, venues, and contribution statements associated with the documented publications.

Research Contributions

Based on the supplied information, Soliman’s research profile is situated within pharmaceutical sciences and the institutional domain of pharmaceutical technology and regulatory affairs. The available record supports recognition of an emerging scholarly trajectory rather than a definitive assessment of a specific research breakthrough. Detailed contribution analysis should examine the originality, scientific methodology, reproducibility, and practical or regulatory relevance of individual publications.

  • Development of scholarly activity within pharmaceutical sciences.
  • Engagement with research at the intersection of pharmaceutical technology and regulatory affairs.
  • Establishment of an emerging citation and publication record.
  • Potential for continued interdisciplinary research and professional development.

Publications

The supplied profile reports five scholarly documents associated with the researcher. Individual publication titles, journals, publication years, authorship positions, and DOI identifiers were not provided in the source information supplied for this page. Consequently, specific publications and DOI records should be verified against authoritative bibliographic databases before being added to a formal publication list. This approach avoids attributing publications or identifiers without adequate source verification.

Research Impact

The supplied metrics indicate 23 citations across five documents and an h-index of 3. Citation counts can provide an indication of scholarly uptake, but their interpretation depends on field, publication age, document type, collaboration patterns, and database coverage. [2] For a young researcher, these indicators may be considered as part of a broader assessment that includes research quality, contribution to collaborative projects, methodological development, and prospects for future work.

Award Suitability

Lomass Soliman’s supplied academic profile is consistent with the general concept of a Young Researcher Award because it documents active scholarly work in Pharmaceutical Sciences and an identifiable record of publications and citations. The affiliation with the University of Szeged further establishes an academic research context. Final award eligibility and selection, however, should be determined according to the official criteria of the International Research Awards on Network Science & Graph Analytics and through the event’s formal review process.

Relevant evaluation may include the quality and originality of publications, demonstrated research contribution, academic progression, scholarly visibility, and the potential for continued impact. The current bibliometric indicators can serve as supporting evidence but should not substitute for peer or committee assessment.

Conclusion

Lomass Soliman represents an emerging researcher in Pharmaceutical Sciences affiliated with the University of Szeged in Hungary. The supplied record of five documents, 23 citations, and an h-index of 3 provides a measurable foundation for evaluating early scholarly development.

Within the Young Researcher Award context, the profile may be considered alongside publication quality, research originality, contribution, and future potential. Further bibliographic verification and review of individual research outputs would strengthen a comprehensive assessment.

References

  1. International Committee of Medical Journal Editors. (n.d.). Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals.https://www.icmje.org/recommendations/
  2. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.https://doi.org/10.1073/pnas.0507655102
  3. Google Scholar. (n.d.). Google Scholar profile: Lomass Soliman, profile ID BPP-6osAAAAJ.https://scholar.google.com/citations?hl=en&user=BPP-6osAAAAJ
  4. University of Szeged. (n.d.). Institute of Pharmaceutical Technology and Regulatory Affairs.https://www.u-szeged.hu/

Azar Tahghighi | Molecular Docking & Molecular Dynamic | Research Excellence Award

Published on by Network Science

Research Excellence Award

Azar Tahghighi
Pastur Institute of Iran
Azar Tahghighi
Affiliation Pastur Institute of Iran
Country Iran
Scopus ID 24923832500
Documents 47
Citations 728
h-index 15
Subject Area Molecular Docking & Molecular Dynamic
Event International Research Awards on Network Science & Graph Analytics
ORCID 0000-0002-1221-4490

Azar Tahghighi is a researcher affiliated with the Pastur Institute of Iran whose scholarly activities span molecular docking, molecular dynamics simulations, medicinal chemistry, antimicrobial discovery, and computational drug design. Her body of work integrates in silico methodologies with experimental validation to investigate biologically active compounds, receptor-ligand interactions, and novel therapeutic candidates. Through contributions to peer-reviewed scientific literature, she has participated in advancing contemporary approaches for drug discovery and biological target identification.[1]

Abstract

This article summarizes the academic achievements and research contributions of Azar Tahghighi in the fields of medicinal chemistry and computational molecular sciences. Her research portfolio emphasizes molecular docking, molecular dynamics, pharmacophore modeling, antimicrobial agent discovery, and receptor-targeted therapeutic development. By combining computational prediction with laboratory validation, her work contributes to the identification of biologically relevant compounds and supports contemporary drug discovery strategies.[2]

Keywords

Molecular Docking, Molecular Dynamics, Medicinal Chemistry, Drug Discovery, TLR7 Ligands, Pharmacophore Modeling, Antibacterial Agents, Antibiofilm Activity, Computational Biology, Virtual Screening.

Introduction

Modern pharmaceutical research increasingly relies on computational techniques to accelerate therapeutic discovery and optimize candidate selection. Azar Tahghighi’s research aligns with this interdisciplinary trend by integrating computational chemistry, structural biology, and medicinal chemistry approaches. Her studies frequently investigate molecular interactions and biological pathways relevant to infectious diseases, immune modulation, and antimicrobial resistance.[3]

Research Profile

According to available scholarly metrics, the researcher has produced 47 indexed documents, accumulated 728 citations, and achieved an h-index of 15. Her scientific activities encompass molecular docking, molecular dynamic simulations, synthetic medicinal chemistry, receptor-targeted drug design, and antimicrobial evaluation. These contributions reflect sustained engagement with computational and experimental biomedical research.[1]

Research Contributions

  • Development of novel triazoloquinoxaline derivatives targeting Toll-like receptor 7.
  • Application of pharmacophore-based virtual screening and molecular docking techniques.
  • Investigation of antibacterial and antibiofilm compounds against resistant pathogens.
  • Research on probiotic-derived antibacterial extracts and microbial control strategies.
  • Evaluation of green chemistry approaches for antifungal drug synthesis.

Publications

  • Structure-guided design of triazolo[4,3-a] quinoxaline-4-ol derivatives as novel TLR7 ligands (2026).
  • Identification of new triazoloquinoxaline amine derivatives against Toll-like receptor 7 (2025).
  • Antibacterial and Antibiofilm Efficacy against MRSA (2025).
  • Click chemistry for green synthesis of antifungal medications (2024).
  • Anti-bacterial and anti-biofilm activity of probiotic Lactobacillus extracts (2024).

Research Impact

The research output demonstrates the practical application of computational methodologies for identifying promising therapeutic candidates. Publications addressing immune receptor modulation, antimicrobial resistance, and medicinal chemistry contribute to scientific understanding in areas of ongoing biomedical importance. Citation performance further indicates that her work has received recognition within relevant academic communities.[4]

Award Suitability

Azar Tahghighi’s multidisciplinary research profile demonstrates sustained scholarly productivity, measurable citation impact, and active engagement in computational and experimental biomedical sciences. Her contributions to molecular modeling, medicinal chemistry, and antimicrobial research align with the principles of research excellence recognized by international scientific award programs. The combination of publication quality, innovation, and translational relevance supports consideration for academic recognition.[5]

Conclusion

Azar Tahghighi has established a research portfolio focused on computational drug discovery, medicinal chemistry, and antimicrobial innovation. Through a combination of molecular modeling techniques and laboratory-based investigations, her work contributes to advancing therapeutic development and biological target evaluation. These accomplishments reflect a meaningful contribution to contemporary biomedical research and scientific scholarship.[6]

References

  1. Elsevier. (n.d.). Scopus author details: Azar Tahghighi, Author ID 24923832500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=24923832500
  2. Chemical Physics Impact. (2026). Structure-guided design of triazolo[4,3-a] quinoxaline-4-ol derivatives as novel TLR7 ligands.
    https://doi.org/10.1016/j.chphi.2026.101045
  3. PLOS One. (2025). Identification of new triazoloquinoxaline amine derivatives with potent modulatory effects against Toll-like receptor 7.
    https://doi.org/10.1371/journal.pone.0336701
  4. Journal of Medical Microbiology and Infectious Diseases. (2025). Antibacterial and Antibiofilm Efficacy of a Synthetic Nitrofuranyl Pyranopyrimidinone Derivative.
    https://doi.org/10.61882/JoMMID.13.2.139
  5. Chemical Biology & Drug Design. (2024). Click chemistry beyond metal-catalyzed cycloaddition as a tool for antifungal medication synthesis.
    https://doi.org/10.1111/cbdd.14555
  6. Iranian Biomedical Journal. (2024). Evaluation of Anti-Bacterial and Anti-Biofilm Activity of Native Probiotic Strains of Lactobacillus Extracts.
    https://doi.org/10.61186/ibj.4043